227 related articles for article (PubMed ID: 23097668)
1. Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists.
Ikeda K; Isaka T; Fujioka K; Manome Y; Tojo K
Int J Endocrinol; 2012; 2012():519467. PubMed ID: 23097668
[TBL] [Abstract][Full Text] [Related]
2. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
3. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
[TBL] [Abstract][Full Text] [Related]
4. New approaches to blockade of the renin-angiotensin-aldosterone system: mineralocorticoid-receptor blockers exert antihypertensive and renoprotective effects independently of the renin-angiotensin system.
Nishiyama A; Hasegawa K; Diah S; Hitomi H
J Pharmacol Sci; 2010; 113(4):310-4. PubMed ID: 20675957
[TBL] [Abstract][Full Text] [Related]
5. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
8. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
[TBL] [Abstract][Full Text] [Related]
9. [Aldosterone-to-renin ratio threshold for screening primary aldosteronism in Chinese hypertensive patients].
Chen SX; Du YL; Zhang J; Gong YC; Hu YR; Chu SL; He QB; Song YY; Zhu DL
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):868-72. PubMed ID: 17217708
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.
Sato A; Saruta T; Funder JW
Hypertens Res; 2006 Apr; 29(4):211-6. PubMed ID: 16778327
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological treatment of aldosterone excess.
Deinum J; Riksen NP; Lenders JW
Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
[TBL] [Abstract][Full Text] [Related]
12. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
Gerc V; Buksa M; Loza V; Kulic M
Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
[TBL] [Abstract][Full Text] [Related]
13. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
14. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
Mercier K; Smith H; Biederman J
Prim Care; 2014 Dec; 41(4):765-78. PubMed ID: 25439533
[TBL] [Abstract][Full Text] [Related]
15. Saga of renin-angiotensin system and calcium channels in hypertensive diabetics: does it have a therapeutic edge?
Kumar AH; Ramarao P
Cardiovasc Drug Rev; 2005; 23(2):99-114. PubMed ID: 16007228
[TBL] [Abstract][Full Text] [Related]
16. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
Zhao HJ; Li Y; Liu SM; Sun XG; Li M; Hao Y; Cui LQ; Wang AH
Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
[TBL] [Abstract][Full Text] [Related]
17. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
Werner C; Pöss J; Böhm M
Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?
Rossi GP
Curr Hypertens Rep; 2006 Jun; 8(3):262-8. PubMed ID: 17147926
[TBL] [Abstract][Full Text] [Related]
19. The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.
Li XC; Zhang J; Zhuo JL
Pharmacol Res; 2017 Nov; 125(Pt A):21-38. PubMed ID: 28619367
[TBL] [Abstract][Full Text] [Related]
20. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
